HIV-associated anemia after 96 weeks on therapy: Determinants Across Age Ranges in Uganda and Zimbabwe

AIDS Research and Human Retroviruses

Volumn 30, Issue 6, 2014, Pages 523-530

  Jaganath, Devan ^a   Walker, A Sarah ^b   Ssali, Francis ^c   Musiime, Victor ^c   Kiweewa, Francis ^c   Kityo, Cissy ^c   Salata, Robert ^d   Mugyenyi, Peter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; MULTIVITAMIN; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED ANEMIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON THERAPY; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; MICROCYTIC ANEMIA; MICROCYTOSIS; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; NORMOCYTIC ANEMIA; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; UGANDA; YOUNG ADULT; ZIMBABWE; AGE; AGED; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; TIME FACTORS; UGANDA; YOUNG ADULT; ZIMBABWE;

EID: 84902188911     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0255     Document Type: Article

References (45)

1. Benoist B, McLean E, Egll I, and Cogswell M Worldwide Prevalence of Anaemia 1993-2005 WHO Global Database on Anaemia (de Benoist B, ed.). World Health Organization, Geneva, Switzerland, 2008.
2. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, and Saag M Anemia in HIV infection Clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38(10)1454-1463. (Pubitemid 38668593)
3. Calis JCJ, van Hensbroek MB, de Haan RJ, Moons P, Brabin BJ, and Bates I HIV-associated anemia in children A systematic review from a global perspective. AIDS 2008;22(10)1099.
4. Volberding P Consensus statement Anemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther 2000;22(9)1004-1020.
5. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999;13(8)943-950. (Pubitemid 29240189)
6. Wisaksana R, Sumantri R, Indrati AR, et al. Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. BMC Infect Dis 2011;11(1)213.
7. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, and Fawzi WW Anemia is an independent predictor of mortality and immunologic progression of Disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005;40(2)219-225. (Pubitemid 41395722)
8. Johannessen A, Naman E, Gundersen SG, and Bruun JN Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis 2011;11(1)190.
9. Moore RD and Forney D Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29(1)54.
10. Mildvan D, Creagh T, and Leitz G Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients Findings of the Anemia Prevalence Study. Curr Med Res Opin 2007;23(2)343-355. (Pubitemid 46333383)
11. Owiredu W, Quaye L, N A, and Addai-Mensah O Prevalence of anaemia and immunological markers among Ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci 2011;11(1)2-15.
12. Giganti MJ, Limbada M, Mwango A, et al. Six-month hemoglobin concentration and its association with subsequent mortality among adults on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2012;61(1)120-123.
13. Mugyenyi P, Walker A, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART) A randomised noninferiority trial. Lancet 2010;375(9709)123-131.
14. Kekitiinwa A, Cook A, Nathoo K, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW) A 5-year open-label randomised factorial trial. Lancet 2013;381(9875)1391-1403.
15. WHO Antiretroviral Therapy of HIV Infection in Infants and Children Towards Universal Access Recommendations for a Public Health Approach. World Health Organization, Geneva, 2006.
16. DART Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy A randomized double-blind trial (NORA). Trop Med Int Health 2008;13(1)6-16.
17. WHO Iron Deficiency Anaemia Assessment, Prevention and Control A Guide for Programme Managers. World Health Organization, Geneva, 2001.
18. Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, and Philippe J Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg 2011;84(3)456-460.
19. UNAIDS 2012 Progress reports submitted by countries. 2012. www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/ 2012countries/. Accessed September 11, 2013.
20. Negin J and Cumming RG HIV infection in older adults in sub-Saharan Africa Extrapolating prevalence from existing data. Bull World Health Organ 2010;88(11)847-853.
21. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging State of knowledge and areas of critical need for research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012;60;S1-S18.
22. Vanasse GJ and Berliner N Anemia in elderly patients An emerging problem for the 21st century. Hematology Am Soc Hematol Educ Program 2010;2010(1)271-275.
23. de Pee S and Semba RD Role of nutrition in HIV infection Review of evidence for more effective programming in resource-limited settings. Food Nutr Bull 2010;31(Suppl 4)313S-344S.
24. Eley BS, Sive AA, Shuttleworth M, and Hussey GD A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town, South Africa. BMC Infect Dis 2002;2(1)3.
25. Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, and Semba RD Iron deficiency anemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. J Nutr 2002;132(3)423-429. (Pubitemid 34208744)
26. Shet A, Arumugam K, Rajagopalan N, et al. The prevalence and etiology of anemia among HIV-infected children in India. Eur J Pediatr 2012;171(3)531-540.
27. Obirikorang C and Yeboah FA Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. J Biomed Sci 2009;16;102.
28. Ssali F, Stöhr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudinecontaining regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006;11(6) 741-749. (Pubitemid 44497169)
29. Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55(12)1707-1718.
30. Anude C, Eze E, Onyegbutulem H, et al. Immunovirologic outcomes and immuno-virologic Discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis 2013;13(1)113.
31. Labhardt ND, Lejone T, Setoko Ml, et al. A clinical prediction score in addition to WHO criteria for anti-retroviral treatment failure in resource-limited settings-experience from Lesotho. PLoS One 2012;7(10)e47937.
32. Sullivan PS, Hanson DL, and Brooks JT Impact on hemoglobin of starting combination antiretroviral therapy with or without zidovudine in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2008;48(2) 163-168.
33. Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, and Chilongola J The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci 2012;12(1)2-7.
34. WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection Recommendations for a Public Health Approach. World Health Organization, Geneva, 2013.
35. Munyazesa E, Emile I, Mutimura E, et al. Assessment of haematological parameters in HIV-infected and uninfected Rwandan women A cross-sectional study. BMJ Open 2012;2(6).
36. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, and Vlahov D Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and uninfected women. Clin Infect Dis 2002;34(2)260-266. (Pubitemid 34030579)
37. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2001;26(1)28-35. (Pubitemid 32115048)
38. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, and Sterling TR Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. PLoS One 2012;7(9)e44999.
39. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, and Subramanian S Anaemia in low-income and middle-income countries. Lancet 2012;378(9809)2123- 2135.
40. Mehta S, Spiegelman D, Aboud S, et al. Lipid-soluble vitamins A, D, and E in HIV-infected pregnant women in Tanzania. Eur J Clin Nutr 2010;64(8)808-817.
41. Kupka R, Msamanga GI, Mugusi F, Petraro P, Hunter DJ, and Fawzi WW Iron status is an important cause of anemia in HIV-infected Tanzanian women but is not related to accelerated HIV Disease progression. J Nutr 2007;137(10)2317- 2323. (Pubitemid 47529596)
42. Baltazary G, Akarro R, and Mussa A Some factors associated with non-adherence to antiretroviral therapy (ART) in people living with HIV/AIDS (PLHA) in Tanzania A case study of Dar es Salaam region. East Afr J Public Health 2011;8(4)237.
43. Fawzi WW, Msamanga GI, Kupka R, et al. Multivitamin supplementation improves hematologic status in HIV-infected women and their children in Tanzania. Am J Clin Nutr 2007;85(5)1335-1343. (Pubitemid 46740477)
44. Gebo KA Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 2008;4(6)615-627.
45. Battegay M, Fehr J, Flückiger U, and Elzi L Antiretroviral therapy of late presenters with advanced HIV Disease. J Antimicrob Chemother 2008;62(1)41-44. (Pubitemid 351865872)